Teladoc Health (NYSE:TDOC) Releases FY 2026 Earnings Guidance

Teladoc Health (NYSE:TDOC) updated its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of -1.000–0.750 for the period, compared to the consensus estimate of -0.810. The company issued revenue guidance of $2.4 billion-$2.4 billion, compared to the consensus revenue estimate of $2.5 billion. Teladoc Health also updated its Q3 2026 guidance to -0.300–0.200 EPS.

Teladoc Health Price Performance

Shares of NYSE:TDOC traded up $0.07 during midday trading on Friday, reaching $6.66. The company’s stock had a trading volume of 2,899,481 shares, compared to its average volume of 5,524,203. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72. The business’s fifty day simple moving average is $8.21 and its 200-day simple moving average is $6.54. Teladoc Health has a fifty-two week low of $4.40 and a fifty-two week high of $9.89. The company has a market capitalization of $1.20 billion, a P/E ratio of -6.72 and a beta of 2.10.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. The business had revenue of $606.93 million for the quarter, compared to the consensus estimate of $615.44 million. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.02%. Teladoc Health’s revenue for the quarter was down 4.0% on a year-over-year basis. During the same period last year, the company posted ($0.19) EPS. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. As a group, equities research analysts expect that Teladoc Health will post -0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

TDOC has been the topic of a number of research reports. Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Canaccord Genuity Group dropped their target price on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday. Citigroup lifted their price target on Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a report on Tuesday, May 5th. Finally, Bank of America raised their price objective on Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Tuesday, July 7th. Five investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Teladoc Health currently has an average rating of “Hold” and an average price target of $7.50.

Insider Transactions at Teladoc Health

In related news, CEO Charles Divita III sold 19,132 shares of Teladoc Health stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $145,977.16. Following the completion of the sale, the chief executive officer directly owned 389,894 shares of the company’s stock, valued at approximately $2,974,891.22. This trade represents a 4.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Carlos Nueno sold 6,196 shares of the company’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $47,275.48. Following the completion of the transaction, the insider directly owned 57,671 shares in the company, valued at approximately $440,029.73. This represents a 9.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 39,195 shares of company stock worth $299,058 over the last three months. Company insiders own 0.70% of the company’s stock.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a second-quarter adjusted loss of $0.21 per share, better than the $0.24 loss analysts expected. Integrated Care and international operations helped offset weakness in BetterHelp, while first-half losses narrowed, suggesting efficiency initiatives are making progress. Teladoc Health Q2 Earnings Beat Estimates on Integrated Care Strength
• Positive Sentiment: Canaccord Genuity maintained a “buy” rating despite lowering its price target from $11 to $10, implying substantial upside from recent trading levels. Increased call-option activity also indicates that some traders are positioning for a rebound. Canaccord Lowers Teladoc Price Target
• Neutral Sentiment: Teladoc generated $64.7 million in operating cash flow and ended the quarter with $774.3 million in cash and equivalents, providing liquidity while the company works to stabilize revenue and reach sustained profitability. Teladoc Health Reports Second Quarter 2026 Results
• Negative Sentiment: Second-quarter revenue fell 4% year over year to $606.9 million, missing the roughly $615.4 million consensus estimate. The company posted a $38.9 million net loss, or $0.21 per share, compared with a $0.19 loss a year earlier. Teladoc Tumbles on Revenue Forecast Cut
• Negative Sentiment: Management reduced full-year 2026 revenue guidance to approximately $2.4 billion, below the $2.5 billion analyst consensus. Third-quarter revenue guidance of $569 million to $609 million and an adjusted loss of $0.30 to $0.20 per share were also below expectations. Why Teladoc Health Stock Is Dropping Following Soft Q3 Outlook
• Negative Sentiment: The primary concern is a shift in BetterHelp demand, including lower cash-pay revenue, which overshadowed strength in Integrated Care and raised doubts about Teladoc’s near-term growth and profit trajectory.

Hedge Funds Weigh In On Teladoc Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TDOC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Teladoc Health by 2.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock worth $1,542,000 after purchasing an additional 5,235 shares during the period. NewEdge Advisors LLC boosted its position in shares of Teladoc Health by 1,278.7% during the 1st quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock worth $90,000 after acquiring an additional 10,485 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Teladoc Health by 5.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock valued at $3,566,000 after purchasing an additional 24,124 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Teladoc Health during the first quarter worth $615,000. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of Teladoc Health in the 2nd quarter valued at $89,000. 76.82% of the stock is owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.